-+ 0.00%
-+ 0.00%
-+ 0.00%

ERASCA - PHASE 3 TRIAL IN 1L RAS-MUTANT NSCLC EXPECTED TO INITIATE H2 2027-H1 2028

Reuters·11/20/2026 12:02:01